Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vor Biopharma Inc (VOR)

Vor Biopharma Inc (VOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,799
  • Shares Outstanding, K 68,260
  • Annual Sales, $ 0 K
  • Annual Income, $ -117,863 K
  • 60-Month Beta -0.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade VOR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-0.45 on 05/09/24
  • Next Earnings Date 08/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 506.04% ( -30.15%)
  • Historical Volatility 66.63%
  • IV Percentile 98%
  • IV Rank 57.91%
  • IV High 844.30% on 01/23/24
  • IV Low 40.55% on 07/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,867
  • Open Int (30-Day) 3,860

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.36
  • Low Estimate -0.47
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +8.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9000 +2.22%
on 07/05/24
1.3200 -30.30%
on 06/11/24
-0.3900 (-29.77%)
since 06/05/24
3-Month
0.9000 +2.22%
on 07/05/24
2.2200 -58.56%
on 04/08/24
-1.2400 (-57.41%)
since 04/05/24
52-Week
0.9000 +2.22%
on 07/05/24
3.4800 -73.56%
on 07/21/23
-1.9900 (-68.38%)
since 07/05/23

Most Recent Stories

More News
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 22.03 (-4.67%)
PRTC.LN : 186.800 (+1.19%)
BIIB : 225.65 (+0.46%)
KRTX : 329.83 (+0.03%)
VOR : 0.9080 (-1.30%)
AKLI : 0.4320 (-0.62%)
PureTech Provides End of Year Report on Key Progress

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today...

PRTC : 22.03 (-4.67%)
PRTC.LN : 186.800 (+1.19%)
KRTX : 329.83 (+0.03%)
GLS : 0.1586 (+0.38%)
VOR : 0.9080 (-1.30%)
AKLI : 0.4320 (-0.62%)
BIIB : 225.65 (+0.46%)
PureTech Health plc – Half-Year Report

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its half-yearly results for the six months ended June 30, 2022. The following information will be filed...

PRTC : 22.03 (-4.67%)
PRTC.LN : 186.800 (+1.19%)
AKLI : 0.4320 (-0.62%)
GLS : 0.1586 (+0.38%)
DNAA : 14.07 (+47.02%)
RBLX : 38.68 (+2.41%)
CPSR : 7.36 (+9.85%)
KRTX : 329.83 (+0.03%)
VOR : 0.9080 (-1.30%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 0.9080 (-1.30%)
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Multiplex deletion of myeloid antigens CD33 and CLL-1 in human hematopoietic stem cells demonstrates potential of next-generation HSC transplants for...

VOR : 0.9080 (-1.30%)
Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it...

VOR : 0.9080 (-1.30%)
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update

Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant...

VOR : 0.9080 (-1.30%)
Vor Bio Announces Retirement of Chief Medical Officer

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that...

VOR : 0.9080 (-1.30%)
Vor Biopharma Enters Oversold Territory (VOR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

VOR : 0.9080 (-1.30%)
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases

Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement...

VOR : 0.9080 (-1.30%)

Business Summary

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.0394
2nd Resistance Point 1.0088
1st Resistance Point 0.9644
Last Price 0.9080
1st Support Level 0.8894
2nd Support Level 0.8588
3rd Support Level 0.8144

See More

52-Week High 3.4800
Fibonacci 61.8% 2.4944
Fibonacci 50% 2.1900
Fibonacci 38.2% 1.8856
Last Price 0.9080
52-Week Low 0.9000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar